SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-044282
Filing Date
2024-04-05
Accepted
2024-04-05 16:15:50
Documents
7
Period of Report
2024-05-08

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm242674-1_def14a.htm DEF 14A 1053814
2 GRAPHIC lg_theravanbiopharma-4c.jpg GRAPHIC 49258
3 GRAPHIC sg_rickewinningham-bw.jpg GRAPHIC 5530
4 GRAPHIC bc_theravance-4c.jpg GRAPHIC 68093
5 GRAPHIC bc_netincome-4c.jpg GRAPHIC 74479
6 GRAPHIC px_24theravproxy1pg1-4c.jpg GRAPHIC 388684
7 GRAPHIC px_24theravproxy1pg2-4c.jpg GRAPHIC 274853
  Complete submission text file 0001104659-24-044282.txt   2190828
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36033 | Film No.: 24826710
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)